Hepatic Events and Viral Kinetics in Hepatocellular Carcinoma Patients Treated with Atezolizumab plus Bevacizumab

INTRODUCTION: In the Phase 3 IMbrave150 trial (NCT03434379), atezolizumab + bevacizumab demonstrated a clinically meaningful survival benefit over sorafenib in patients with unresectable hepatocellular carcinoma (HCC), including those with hepatitis B virus (HBV) or hepatitis C virus (HCV) infection...

Descripción completa

Detalles Bibliográficos
Autores principales: Hsu, Chiun, Ducreux, Michel, Zhu, Andrew X., Qin, Shukui, Ikeda, Masafumi, Kim, Tae-You, Galle, Peter R., Finn, Richard S., Chen, Ethan, Ma, Ning, Hu, Youyou, Li, Lindong, Cheng, Ann-Lii
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9982337/
https://www.ncbi.nlm.nih.gov/pubmed/36872921
http://dx.doi.org/10.1159/000525499

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9982337/
https://www.ncbi.nlm.nih.gov/pubmed/36872921
http://dx.doi.org/10.1159/000525499

Ejemplares similares